The DRAGON 2 Trial

In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).

Trial Details

NCT ID
NCT05428735
Phase
NA
Sponsor
Maastricht University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Embolization
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Clayton, Victoria, Australia|-37.91667,145.11667
  • Vienna, State of Vienna, Austria|48.20849,16.37208
  • Brussels, Brussels Capital, Belgium|50.85045,4.34878
  • Liège, Liège, Belgium|50.63373,5.56749

Key Eligibility Criteria

  • Patients with primarily unresectable/ potentially resectable CRLM with a FLR \<30% (\<40% in chemotherapy damaged livers)
  • Patients with non-resected primary CRC may be included if there is an intention to resect the CRC after the liver treatment (liver first approach) …
  • Patients with resectable or ablatable lung or brain metastases can be included (statement about the resectability of these extrahepatic metastases …
  • 18 Years and older

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →